⚠ The Cost Argument Weakens Where Laparoscopy Is Already GoodHigh threat

The value proposition is comparative: a da Vinci procedure has to beat the next-best alternative on outcomes and total cost. Where the alternative is open surgery, that is an easy argument. Where the alternative is a mature laparoscopic technique performed well and cheaply, it is not.

Intuitive makes the concession itself, twice. On cholecystectomy: "given the already very high level of laparoscopic techniques used in cholecystectomy procedures, it remains unclear to what extent robotic-assisted surgery using da Vinci may continue to be adopted." On appendectomy: "similar to cholecystectomy procedures, there is currently a high level of laparoscopic techniques used"¹. Both were named among the largest contributors to United States general surgery growth in 2025².

That is the awkward shape of the current growth. The categories adding the most procedures are the ones where the incumbent technique is already minimally invasive, already fast and already cheap — so the incremental clinical benefit is smaller and the incremental cost is the same $1,825 of instruments. The categories where robotics is most clearly superior, such as prostatectomy, are largely converted already; United States urology grew 8% in 2025 against general surgery's 18%.

The implication is that as the mix shifts toward high-volume benign general surgery, Intuitive is selling into an argument that gets harder each year, to hospitals under cost pressure, for patients whose insurance may or may not cover it.

Watch the United States general-surgery growth rate against the price per procedure. Volume holding while consumable revenue per case falls would mean Intuitive is buying that volume with price.